T2 Biosystems’ recent Breakthrough Device designation by the FDA isn’t an acknowledgement of the device’s effectiveness or clinical value proposition, only that it diagnoses life-threatening conditions.
The T2Dx Instrument adds additional hospital expense but provides little clinical value, hence the miniscule sales numbers.
The value of the T2Bacteria test is low because it does not measure bacterial susceptibility to antibiotics and, therefore, does not change clinical practice. Other similar technologies have been flops.
In every 2018 quarter, TTOO’s unsustainable research revenue was higher than its much more important product revenue.
TTOO has $44M in debt, paying interest at an usurious 12.5% rate.
As previously reported, T2 Biosystems was notified by the NASDAQ on November 22, 2022 that it was not in compliance with the NASDAQ's Capital Market requirement because it failed to maintain a MVLS of at least $35 million for a period of 30 consecutive business days.
The average analyst rating for T2 Biosystems stock from 2 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
T2 Biosystems (TTOO) reported a weak preliminary third-quarter earnings report. The company's shares also began trading on a 1-for-100 reverse split-adjusted basis as of this morning. TTOO stock is down by more than 65% for the past week.
(NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that on October 31, 2023 it received written notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company regained ...
The T2Dx Instrument adds additional hospital expense but provides little clinical value, hence the miniscule sales numbers. The value of the T2Bacteria test is low because it does not measure bacterial susceptibility to antibiotics and, therefore, does not change clinical practice.
The T2 Biosystems stock prediction for 2025 is currently $ 5.57, assuming that T2 Biosystems shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a -3.31% increase in the TTOO stock price.
The average price target for T2 Biosystems is $3.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $3.00 ,the lowest forecast is $3.00. The average price target represents -43.50% Decrease from the current price of $5.31.
The T2 Biosystems stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average.
The main competitors of T2 Biosystems include Neuronetics (STIM), Pro-Dex (PDEX), Lyra Therapeutics (LYRA), Accuray (ARAY), Alpha Tau Medical (DRTS), TriSalus Life Sciences (TLSI), ClearPoint Neuro (CLPT), Quipt Home Medical (QIPT), TELA Bio (TELA), and KORU Medical Systems (KRMD).
Target's stock dives after profit misses, as many Americans have 'maxed out' Shares of Target Corp. took a dive Wednesday, toward their biggest selloff in nearly two years, after the discount retail giant reported fiscal first-quarter profit that missed expectations, amid weakness in sales of discretionary items.
(TTOO) will effect a one-for-one hundred (1-100) reverse split of its Common Stock. The reverse stock split will become effective on Friday, October 13, 2023. In conjunction with the reverse split, the CUSIP number will change to 89853L302.
T2Bacteria and T2Candida are the first and only FDA-cleared diagnostic tests to provide species identification of sepsis-causing bacterial and fungal pathogens, directly from a whole blood sample, independent of a positive blood culture.
The T2Bacteria Panel (T2 Biosystems) is a direct-from-blood, nonculture test that identifies the most common ESKAPE bacteria (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Escherichia coli).
Introduction: My name is Jonah Leffler, I am a determined, faithful, outstanding, inexpensive, cheerful, determined, smiling person who loves writing and wants to share my knowledge and understanding with you.
We notice you're using an ad blocker
Without advertising income, we can't keep making this site awesome for you.
American Superconductor Is A House Of Cards Set To Blow Over By A Gust Of Wind...